"It is really unclear what the implications are" of appeals court ruling in Bristol v. Ivax generic paclitaxel case, Bristol says. Appellate court upheld findings of district court on eight of 10 patent claims, but ruled that two pre-medication claims should proceed to trial. "We're basing our plan for the remainder of this year and going forward on the assumption that we'll have generic competition in the U.S.," Bristol says, but "we will pursue whatever avenues are available to us on the legal side." U.S. Taxol sales fell 32% during the quarter to $180 mil. in the face of generic competition from Ivax
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth